As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression,…
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose…
ST. LOUIS, May 23, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment…
Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12…
Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternativesLEXINGTON, Mass., May 23, 2023…
LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens…
The T2Biothreat Panel detects six biothreat pathogens and runs on the FDA-cleared T2Dx InstrumentLEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE)…
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ETNAARDEN, the Netherlands and MIAMI,…
Vanderbilt Medical Center May 22, 2023 Amsterdam, the Netherlands and Nashville, TN, USA – Royal Philips (NYSE: PHG, AEX: PHIA),…
ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT)…